Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: Preliminary results of the BOLERO-2 trial

被引：0
|
作者：
Baselga, J.
Campone, M.
Piccart-Gebhart, M. J.
Burris, H. A.
Rugo, H. S.
Noguchi, S.
Gnant, M.
Pritchard, K. I.
Lebrun, F.
Beck, J. T.
Ito, Y.
Yardley, D. A.
Deleu, I.
Perez, A.
Bachelot, T. D.
Vittori, L.
Mukhopadhyay, P.
Weber, D.
Sahmoud, T.
Hortobagyi, G. N.
机构：
[1] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[2] Ctr Rene Gauducheau, St Herblain, France
[3] Inst Jules Bordet, B-1000 Brussels, Belgium
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Univ Calif San Francisco, San Francisco, CA 94143 USA
[6] Osaka Univ, Osaka, Japan
[7] Med Univ Vienna, Dept Surg, Ctr Comprehens Canc, Vienna, Austria
[8] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[9] Univ Toronto, Toronto, ON, Canada
[10] Highlands Oncol Grp, Fayetteville, AR USA
[11] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[12] AZ Nikolaas, Ctr Oncol, St Niklaas, Belgium
[13] Mem Canc Inst, Hollywood, FL USA
[14] Ctr Leon Berard, F-69373 Lyon, France
[15] Novartis Pharma AG, Basel, Switzerland
[16] Novartis Pharmaceut, E Hanover, NJ USA
[17] Novartis Pharmaceut, Florham Pk, NJ USA
[18] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11058
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11058
引用
收藏
页数：1
相关论文
共 50 条
  • [1] BOLERO-2: EVEROLIMUS IN COMBINATION WITH EXEMESTANE IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE ADVANCED BREAST CANCER REFRACTORY TO LETROZOLE OR ANASTROZOLE
    Campone, Mario
    Piccart, Martine
    Pritchard, Kathleen I.
    Xu, Cindy
    Gnant, Michael
    Neven, Patrick
    Pistilli, Barbara
    Shtivelband, Mikhail
    Provencher, Louise
    Masuda, Norikazu
    El-Hashimy, Mona
    Vittori, Luc
    Sahmoud, Tarek
    Baselga, Jose
    Hortobagyi, Gabriel N.
    [J]. BREAST, 2011, 20 : S30 - S30
  • [2] Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial
    Baselga, J.
    Campone, M.
    Sahmoud, T.
    Piccart, M.
    Burris, H.
    Rugo, H.
    Noguchi, S.
    Gnant, M.
    Mukhopadhyay, P.
    Hortobagyi, G.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : 6 - +
  • [3] The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer
    Beaver, Julia A.
    Park, Ben H.
    [J]. FUTURE ONCOLOGY, 2012, 8 (06) : 651 - 657
  • [4] Everolimus (EVE) for Postmenopausal Women with Advanced Breast Cancer (ABC) Refractory to Letrozole or Anastrozole: Long-term Efficacy and Safety Results of the BOLERO-2 Trial
    Rugo, H.
    Pritchard, K. I.
    Gnant, M.
    Noguchi, S.
    Piccart, M.
    Hortobagyi, G. N.
    Burris, H. A.
    Bauly, H.
    Sahmoud, T.
    Baselga, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S116 - S116
  • [5] Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer
    Gil J.M.
    Rubio-Terrés C.
    del Castillo-Saiz A.
    González P.
    Canorea F.
    [J]. Clinical and Translational Oncology, 2006, 8 (5) : 339 - 348
  • [6] Everolimus Added to Exemestane Reduced Bone Markers in Postmenopausal Women with Advanced Breast Cancer (ABC): the BOLERO-2 Trial
    Gnant, M.
    Hortobagyi, G. N.
    Rugo, H.
    Burris, H. A.
    Noguchi, S.
    Pritchard, K. I.
    Baselga, J.
    Sahmoud, T.
    Bauly, H.
    Piccart, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S43 - S43
  • [7] Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer
    O'Shaughnessy, J.
    Campone, M.
    Brain, E.
    Neven, P.
    Hayes, D.
    Bondarenko, I.
    Griffin, T. W.
    Martin, J.
    De Porre, P.
    Kheoh, T.
    Yu, M. K.
    Peng, W.
    Johnston, S.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (01) : 106 - 113
  • [8] BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer.
    Noguchi, Shinzaburo
    Masuda, Norikazu
    Ito, Yoshinori
    Iwata, Hiroji
    Mukai, Hirofumi
    Horiguchi, Jun
    Tokuda, Yutaka
    Kuroi, Katsumasa
    Iwase, Hirotaka
    Inaji, Hideo
    Ohsumi, Shozo
    Piccart-Gebhart, Martine J.
    Hortobagyi, Gabriel N.
    Rugo, Hope S.
    Gnant, Michael
    Campone, Mario
    Sahmoud, Tarek
    Pritchard, Kathleen I.
    Burris, Howard A.
    Baselga, Jose
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase Ill Trial.
    Hortobagyi, G. N.
    Piccart, M.
    Rugo, H.
    Burris, H.
    Campone, M.
    Noguchi, S.
    Gnant, M.
    Pritchard, K. I.
    Vittori, L.
    Mukhopadhyay, P.
    Sahmoud, T.
    Lebwohl, D.
    Baselga, J.
    [J]. CANCER RESEARCH, 2011, 71
  • [10] Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.
    Piccart-Gebhart, Martine J.
    Noguchi, Shinzaburo
    Pritchard, Kathleen I.
    Burris, Howard A.
    Rugo, Hope S.
    Gnant, Michael
    Hortobagyi, Gabriel N.
    Melichar, Bohuslav
    Petrakova, Katarina
    Arena, Francis P.
    Xu, Cindy
    Cahana, Ayelet
    Taran, Tanya
    Sahmoud, Tarek
    Lebwohl, David Edward
    Campone, Mario
    Baselga, Jose
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345